This amazing news just in from our friend Dr. Scott Perry :
It has been an exciting journey as PI of Swallowtail, the open label extension study for STK-001, working alongside Stoke Therapeutics to develop disease-modifying therapy for Dravet! Looking forward to continuing this important work and seeing how it impacts the future of people with DravetSyndrome! 
Children with a rare and difficult-to-control form of epilepsy called Dravet syndrome have new hope thanks to landmark research data showing the effectiveness of an RNA-based medicine, STK-001, to improve seizure control and modify disease progression.
The complete article can be found at:
https://www.checkupnewsroom.com/groundbreaking-trial-targets-genetic-cause-of-epilepsy